uniQure (NASDAQ: QURE) shares skyrocketed following a positive regulatory update for AMT-130, its experimental gene therapy for Huntington’s disease. The FDA informed the company that three-year data from its Phase I/II study is acceptable as the primary basis for a Biologics License Application (BLA) for accelerated approval.
This major milestone sparked the massive surge for several key reasons:
- Accelerated Approval Pathway Reinstated: The FDA’s agreement allows uniQure to use existing three-year Phase I/II data, significantly speeding up the commercialization timeline.
- Reversal of Previous Setback: The decision reverses a damaging rejection from March 2026, where the FDA previously stated that existing data was not sufficient and recommended a longer, randomized study.
- Upcoming BLA Submission: With the regulatory path now cleared, uniQure plans to formally submit its application in the third quarter of 2026.
If you’d like, let me know if you want to:
- View the latest uniQure price action and momentum charts.
- Check Wall Street’s consensus rating and QURE analyst forecasts.
